| P50 | author | Sushama Talegaonkar | Q59185733 |
| | Abdul Ahad | Q38546475 |
| | Farhan J. Ahmad | Q42182005 |
| | Mohd Aqil | Q42413205 |
| P2093 | author name string | Naseem Akhtar | |
| | Zeenat Iqbal | |
| | Manu Jaggi | |
| | Roop Kishan Khar | |
| P2860 | cites work | Effect of PSC 833 liposomes and Intralipid on the transport of epirubicin in Caco-2 cells and rat intestines | Q43725876 |
| | Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers | Q44123431 |
| | Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin. | Q44199622 |
| | Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats | Q44485062 |
| | Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias | Q44525292 |
| | Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo | Q44907372 |
| | In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib | Q46073165 |
| | Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats | Q46168447 |
| | Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. | Q46436186 |
| | Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo | Q46487609 |
| | The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis | Q46580597 |
| | Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine | Q46867532 |
| | Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers | Q46892593 |
| | Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. | Q46962350 |
| | Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. | Q52171281 |
| | Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A | Q54307469 |
| | Development and in vivo evaluation of an oral drug delivery system for paclitaxel | Q57355646 |
| | The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line | Q33177639 |
| | Pharmacological strategies for overcoming multidrug resistance | Q33997660 |
| | Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux | Q34028148 |
| | Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs | Q34060806 |
| | P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement | Q35193762 |
| | Multidrug resistance reversal agents | Q35570886 |
| | Structural understanding of efflux-mediated drug resistance: potential routes to efflux inhibition | Q35879831 |
| | Does inhibition of P-glycoprotein lead to drug-drug interactions? | Q36069281 |
| | The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research | Q36365560 |
| | Mechanisms and strategies to overcome multiple drug resistance in cancer | Q36404538 |
| | Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 |
| | A primer on the mechanics of P-glycoprotein the multidrug transporter. | Q36649234 |
| | How can we best use structural information on P-glycoprotein to design inhibitors? | Q36701490 |
| | Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor | Q36788463 |
| | Availability and applications of ATP-binding cassette (ABC) transporter blockers | Q36830826 |
| | Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. | Q36949815 |
| | Natural and synthetic polymers as inhibitors of drug efflux pumps | Q36951710 |
| | Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges | Q37076348 |
| | Structure-activity relationships of tariquidar analogs as multidrug resistance modulators | Q37510736 |
| | Chemical penetration enhancers: a patent review | Q37529814 |
| | Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. | Q37569156 |
| | Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials | Q37635094 |
| | Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles | Q39843746 |
| | Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma | Q40409946 |
| | Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein | Q40582869 |
| | A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro | Q40706801 |
| | Effects of ketoconazole on digoxin absorption and disposition in rat. | Q41027740 |
| | Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor | Q42984640 |
| | Cyclosporin A inhibits the extrusion pump function of p-glycoprotein in the inner ear of mice treated with vinblastine and doxorubicin | Q43614799 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug delivery | Q1392806 |
| P304 | page(s) | 561-576 | |
| P577 | publication date | 2011-02-26 | |
| P1433 | published in | Expert Opinion on Therapeutic Patents | Q5421213 |
| P1476 | title | The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review | |
| P478 | volume | 21 | |